PULSAR - A Prospective Study to Evaluate the Utility of Low Doses of the Statins Atorvastatin and Rosuvastatin.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00329173|
Recruitment Status : Completed
First Posted : May 24, 2006
Last Update Posted : March 16, 2009
|Condition or disease||Intervention/treatment||Phase|
|Hypercholesterolaemia||Drug: Rosuvastatin Drug: Atorvastatin||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||1000 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||A 6-Week Open-Label, Randomised, Multicentre, Phase IIIb, Parallel-Group Study to Compare the Efficacy and Safety of Rosuvastatin (10 mg) With Atorvastatin (20 mg) in Subjects With Hypercholesterolaemia and Either a History of CHD or Clinical Evidence of CHD|
|Study Start Date :||November 2003|
|Actual Study Completion Date :||August 2004|
- Reduction in LDL-c after 6 weeks
- Changes in other lipids and lipoproteins
- Achievement of NCEP -ATP III target goal LDL-Cholesterol and non HDL-C
- Achievement of EAS LDL-c and non HDL-C target goals after 6 weeks treatment.
- Comparison of cost effectiveness and also safety
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00329173
|Study Director:||Crestor Medical Science Director, MD||AstraZeneca|